Kris Kowdley, MD
Gastroenterology · Seattle, WANPI 1699850404
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.9%. 2025 is the largest year on record at $331,375, 2.1 times the $155,248 reported in 2019. Among gastroenterology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 816 payments — averaging $1713.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$321K
- Gilead$254K
- Novo Nordisk$113K
- Ipsen Biopharmaceuticals, Inc$94K
- Boehringer Ingelheim$89K
- Madrigal Pharmaceuticals$89K
- plus $439K from 28 others
Across 1,215 payments — averaging $3713.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$1.2M
- Gilead$644K
- Boehringer Ingelheim International GmbH$492K
- AbbVie$361K
- Ipsen Bioscience Inc.$284K
- Boehringer Ingelheim$243K
- plus $1.3M from 16 others
What the payments were for
- Consulting fees$700,24850%
- Speaking & faculty fees$585,39142%
- Travel & lodging$95,5737%
- Food & beverage$17,1811%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 153 | $320,705 |
| Gilead | 216 | $253,517 |
| Novo Nordisk | 49 | $113,400 |
| Ipsen Biopharmaceuticals, Inc | 32 | $94,171 |
| Boehringer Ingelheim | 70 | $89,219 |
| Madrigal Pharmaceuticals | 52 | $88,842 |
| GSK | 38 | $71,877 |
| Mallinckrodt Hospital Products Inc. | 17 | $53,415 |
| AbbVie | 42 | $51,119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $50,148 |
| Mirum Pharmaceuticals, Inc. | 23 | $48,734 |
| Boehringer Ingelheim International GmbH | 9 | $24,159 |
| Ipsen Bioscience Inc. | 10 | $22,957 |
| Ipsen Innovation | 7 | $22,323 |
| AstraZeneca(2 entities) | 12 | $18,653 |
| Merck | 8 | $16,383 |
| Kowa Research Institute, Inc. | 12 | $12,443 |
| Ipsen Pharma SAS | 2 | $9,545 |
| CSL Behring | 7 | $8,358 |
| Roche Diagnostics International Ltd | 1 | $4,800 |
| Novo Nordisk AS | 1 | $3,375 |
| Albireo Pharma, Inc. | 3 | $3,290 |
| Orphalan Inc | 7 | $3,164 |
| Corcept Therapeutics | 6 | $2,203 |
| Theratechnologies Inc. | 2 | $2,031 |
| Pfizer | 1 | $1,890 |
| Echosens North America, Inc. | 1 | $1,800 |
| Amgen | 1 | $1,800 |
| Dova Pharmaceuticals | 3 | $1,649 |
| Bristol Myers Squibb | 1 | $1,500 |
| Shionogi Inc | 1 | $750 |
| Pentax Of America, Inc. | 1 | $151 |
| Eiger Biopharmaceuticals, Inc. | 1 | $77 |
| Eisai Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,398,478 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 16 | $6,302 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Scott LeeSeattle$220K
- Alyssa ChoiSeattle$102K
- Andrew RossSeattle$99K
- Shayan IraniSeattle$57K
- Laurens JanssensSeattle$56K
- George McDonaldSeattle$53K
- Adam TempletonSeattle$49K
- Sravanthi ParasaSeattle$47K
- Liam HilsonSeattle$37K
- Rotonya CarrSeattle$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.